DevCo Pharmaceuticals, Ltd.
Safety study of Lexipafant completed, phase III commences
Published in Cardiovascular Business Week, April 13th, 2004
Lexipafant is under late stage development for protection from organ dysfunction associated with coronary artery bypass graft (CABG), the treatment of HIV associated cognitive/motor dysfunction, and as a treatment for patients with acute pancreatitis. DevCo also announced that protocols and clinical trial material have been prepared and are available for an immediate start of phase III programs.
The double-blind, placebo-controlled, safety, tolerability, pharmacokinetic and pharmacodynamic study formed part of DevCo's program...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- Bristol-Myers Squibb
ImClone gets $250M related to FDA approval of ERBITUX - Finance
Naturade increases net sales by $1.9 million - Lipid Sciences, Inc.
Biotech company reports 2003 net loss of $11.0 million - NeoPharm, Inc.
Cancer-drug maker reports increased net loss for fourth quarter, year - United Therapeutics Corporation
Biotechnology company announces adoption of 10b5-1 trading plans - World Heart Corporation
Medical device company approved for trading on the NASDAQ National Market - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
